{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:57:43Z","timestamp":1777395463710,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2022,5,17]]},"abstract":"<jats:p>Background: Sporadic cerebral amyloid angiopathy (sCAA) research of the past decade has increasingly focused on developing biomarkers that allow for an earlier and more accurate sCAA-diagnosis. Considering that sCAA does not have treatment options available (yet), more fundamental questions concerning the desirability of using such early-sCAA biomarkers in clinical practice need to be addressed. Objective: In this qualitative interview study, we aim to explore the views of vascular neurologists on the purpose and possible consequences of an earlier and more accurate sCAA-diagnosis, using new biomarkers. Methods: Vascular neurologists from around the world were approached via email and interviewed via video call. Topics included views on current sCAA diagnostic practice, considerations on the use of new biomarkers, and expectations and hopes for the future. All interviews were transcribed ad verbatim using a transcription program (Otter.ai). Transcripts were analyzed using inductive content analysis. Results: We interviewed 14 vascular neurologists. Views regarding the desirability of new sCAA-biomarkers differed substantially between interviewees as to when and in whom these biomarkers could be of benefit in clinical practice. These differences were mainly reported with regards to prognosis, risk stratification, and biological precision, between general stroke neurologists and neurologists with specific sCAA-expertise. Conclusion: Views on the use of sCAA-biomarkers in clinical practice differ substantially between vascular neurologists. There is particularly no consensus regarding when, and in whom sCAA biomarkers could be useful in clinical practice.<\/jats:p>","DOI":"10.3233\/jad-220052","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T11:21:03Z","timestamp":1649157663000},"page":"807-816","source":"Crossref","is-referenced-by-count":0,"title":["Views on the Desirability of Diagnosing Sporadic Cerebral Amyloid Angiopathy with Biological Evidence"],"prefix":"10.1177","volume":"87","author":[{"given":"Herrer","family":"Abdulrahman","sequence":"first","affiliation":[{"name":"Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marthe","family":"Smedinga","sequence":"additional","affiliation":[{"name":"Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel M.","family":"Verbeek","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Radboud Alzheimer Centre, Radboud University Medical Center, Nijmegen, The Netherlands"},{"name":"Radboud Alzheimer Centre, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catharina J.M.","family":"Klijn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edo","family":"Richard","sequence":"additional","affiliation":[{"name":"Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands"},{"name":"Radboud Alzheimer Centre, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke","family":"Perry","sequence":"additional","affiliation":[{"name":"Radboud Alzheimer Centre, Radboud University Medical Center, Nijmegen, The Netherlands"},{"name":"Department of Geriatric Medicine, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-220052_ref1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/alz.12366","article-title":"Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis","volume":"18","author":"J\u00e4kel","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220052_ref2","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1212\/WNL.0000000000003181","article-title":"Recurrent hemorrhage risk and mortality in hereditary and sporadic cerebral amyloid angiopathy","volume":"87","author":"van Etten","year":"2016","journal-title":"Neurology"},{"key":"10.3233\/JAD-220052_ref3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1161\/01.STR.18.2.311","article-title":"Cerebral amyloid angiopathy. A critical review","volume":"18","author":"Vinters","year":"1987","journal-title":"Stroke"},{"key":"10.3233\/JAD-220052_ref4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/STROKEAHA.117.016990","article-title":"Diagnosis of cerebral amyloid angiopathy: Evolution of the Boston Criteria","volume":"49","author":"Greenberg","year":"2018","journal-title":"Stroke"},{"key":"10.3233\/JAD-220052_ref5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ana.410380219","article-title":"Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy","volume":"38","author":"Greenberg","year":"1995","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-220052_ref6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.410300503","article-title":"Cerebral amyloid angiopathy without and with cerebral hemorrhages: A comparative histological study","volume":"30","author":"Vonsattel","year":"1991","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-220052_ref7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00005072-198601000-00007","article-title":"Cerebral amyloid angiopathy: The vascular pathology and complications","volume":"45","author":"Mandybur","year":"1986","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-220052_ref8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1212\/WNL.56.4.537","article-title":"Clinical diagnosis of cerebral amyloid angiopathy: Validation of the Boston criteria","volume":"56","author":"Knudsen","year":"2001","journal-title":"Neurology"},{"key":"10.3233\/JAD-220052_ref9","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1212\/WNL.0000000000001279","article-title":"Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham Heart Study","volume":"84","author":"Shoamanesh","year":"2015","journal-title":"Neurology"},{"key":"10.3233\/JAD-220052_ref10","doi-asserted-by":"crossref","first-page":"e754","DOI":"10.1212\/WNL.0000000000005030","article-title":"Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis","volume":"90","author":"Charidimou","year":"2018","journal-title":"Neurology"},{"key":"10.3233\/JAD-220052_ref11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bioe.12516","article-title":"On the reconceptualization of Alzheimer\u2019s disease","volume":"33","author":"Schermer","year":"2019","journal-title":"Bioethics"},{"key":"10.3233\/JAD-220052_ref12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.31887\/DCNS.2019.21.1\/pwhitehouse","article-title":"Ethical issues in early diagnosis and prevention of Alzheimer disease","volume":"21","author":"Whitehouse","year":"2019","journal-title":"Dialogues Clin Neurosci"},{"key":"10.3233\/JAD-220052_ref14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"key":"10.3233\/JAD-220052_ref15","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","article-title":"Saturation in qualitative research: Exploring its conceptualization and operationalization","volume":"52","author":"Saunders","year":"2018","journal-title":"Qual Quant"},{"key":"10.3233\/JAD-220052_ref16","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qual Health Res"},{"key":"10.3233\/JAD-220052_ref18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMp1006304","article-title":"The path to personalized medicine","volume":"363","author":"Hamburg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-220052_ref20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.nbt.2012.03.004","article-title":"A personal view on systems medicine and the emergence of proactive P4 medicine: Predictive, preventive, personalized and participatory","volume":"29","author":"Hood","year":"2012","journal-title":"N Biotechnol"},{"key":"10.3233\/JAD-220052_ref21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1472-6939-14-55","article-title":"What is personalized medicine: Sharpening a vague term based on a systematic literature review","volume":"14","author":"Schleidgen","year":"2013","journal-title":"BMC Med Ethics"},{"key":"10.3233\/JAD-220052_ref23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/978-1-60327-492-0_13","article-title":"Breast cancer screening and biomarkers","volume":"472","author":"Brooks","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.3233\/JAD-220052_ref24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1600-0447.2008.01326.x","article-title":"Rate of progression of mild cognitive impairment to dementia\u2013meta-analysis of 41 robust inception cohort studies","volume":"119","author":"Mitchell","year":"2009","journal-title":"Acta Psychiatr Scand"},{"key":"10.3233\/JAD-220052_ref25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1017\/S0266462300016147","article-title":"Patient, physician, and payer perceptions and misperceptions of willingness to pay for diagnostic certainty","volume":"16","author":"Hirth","year":"2000","journal-title":"Int J Technol Assess Health Care"},{"key":"10.3233\/JAD-220052_ref26","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1089\/gtmb.2011.0028","article-title":"Willingness to pay for genetic testing for Alzheimer\u2019s disease: A measure of personal utility","volume":"15","author":"Kopits","year":"2011","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.3233\/JAD-220052_ref27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40258-015-0203-4","article-title":"Making good decisions in healthcare with multi-criteria decision analysis: The use, current research and future development of MCDA","volume":"14","author":"M\u00fchlbacher","year":"2016","journal-title":"Appl Health Econ Health Policy"},{"key":"10.3233\/JAD-220052_ref28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3233\/JAD-170813","article-title":"Perspectives on communicating biomarker-based assessments of Alzheimer\u2019s disease to cognitively healthy individuals","volume":"62","author":"Milne","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220052_ref29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11019-018-09883-2","article-title":"Valuing biomarker diagnostics for dementia care: Enhancing the reflection of patients, their care-givers and members of the wider public","volume":"22","author":"van der Burg","year":"2019","journal-title":"Med Health Care Philos"},{"key":"10.3233\/JAD-220052_ref30","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-110-11-893","article-title":"Diagnostic reasoning","volume":"110","author":"Kassirer","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.3233\/JAD-220052_ref31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1370\/afm.348","article-title":"Patient-centered communication and diagnostic testing","volume":"3","author":"Epstein","year":"2005","journal-title":"Ann Fam Med"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-220052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:05:52Z","timestamp":1777370752000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-220052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":27,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-220052","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]}}}